The research collaboration will leverage Exscientia’s precision medicine platform to identify novel anticancer small molecule compounds. Promising candidates will be developed and potentially advanced into clinical trials at MD Anderson. Exscientia uses deep learning multiomics to test drug candidates in patient tissue models.
“We are driven to develop the next generation of oncology treatments that can offer meaningful benefits and improve the lives of our patients,” said Philip Jones, PhD, vice president of therapeutics discovery and head of the Institute for Applied Cancer Science at MD Anderson, in a Nov. 14 news release from the cancer center. “Our ultimate goal is to decrease the time we spend in drug development and accelerate novel targeted therapies into the clinic.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
